From GlobeNewswire: 2025-06-01 07:00:00

Seer, Inc. and Korea University are collaborating on a groundbreaking study to identify early-onset cancer biomarkers in young adults. The study will use Seer’s Proteograph ONE Assay and advanced mass spectrometry technology to analyze 20,000 plasma samples, aiming to improve cancer diagnostics and patient outcomes. The three-year study is funded by the K-Health MIRAE initiative in Korea. By leveraging deep proteomic analysis, the study seeks to develop more sensitive and personalized diagnostics for young adult cancer patients worldwide. Seer’s new Proteograph ONE workflow and Thermo Scientific’s Orbitrap Astral MS are key components driving this transformative research.



Read more at GlobeNewswire: Seer’s Proteograph Platform Enables Unprecedented